Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Longboard Pharmaceuticals Inc (NQ: LBPH ) 36.42 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Longboard Pharmaceuticals Inc < Previous 1 2 3 4 Next > Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome September 26, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome September 19, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Starbucks To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Wednesday September 18, 2024 Via Benzinga Recap: Longboard Pharmaceuticals Q4 Earnings March 12, 2024 Via Benzinga Looking Into Longboard Pharmaceuticals's Recent Short Interest January 19, 2024 Via Benzinga Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage September 10, 2024 Truist Securities initiated coverage on Longboard Pharmaceuticals, citing it as a CNS-focused biotech with high-value epilepsy assets. Via Benzinga Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) September 08, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) September 06, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September August 28, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress August 26, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024 August 26, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) August 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates August 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1 July 29, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire 3 Russell 2000 Growth Stocks That Could Be Worth the Risk July 23, 2024 These three small-cap stocks could deliver hefty returns if the central bank cuts rates. Via The Motley Fool Topics Economy Exposures Interest Rates Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) July 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Top 3 Health Care Stocks That May Crash This Quarter July 03, 2024 Via Benzinga Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352) July 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) June 10, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) June 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) May 06, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire LBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024 May 02, 2024 LBPH stock results show that Longboard Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates May 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15 April 03, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) April 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates March 12, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) March 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) February 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February February 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 26, 2024 Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter. Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.